Efficacy Study of FANG(30) for Active Rheumatoid Arthritis in Adult Patients
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This is a Clinical Pilot Phase II interventional, double blind, randomized and placebo
controlled study to document the efficacy, tolerability and safety of FANG(30) in 60 adult
patients affected with active Rheumatoid Arthritis. Also, to evaluate the effect of an
andrographolide natural formula, identified as FANG(30) or "the study product", on the
immunological functions that influence chronic inflammatory process in these patients, who
could benefit with this treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Juan C. Bertoglio, MD
Collaborator:
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile